Y. Ge

发表

The p53-independent tumoricidal activity of an adenoviral vector encoding a p27-p16 fusion tumor suppressor gene.

J. Gyuris, J. Mcarthur, G. Banik, 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome

A. Schneeweiss, F. Schuetz, C. Sohn, 2012, Cancer Immunology, Immunotherapy.

Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial

A. Schneeweiss, F. Schuetz, C. Sohn, 2013, Cancer Immunology, Immunotherapy.

Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes.

C. Sohn, Y. Ge, J. Rom, 2006, Cancer research.

Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis.

A. Schneeweiss, A. Scharf, F. Schuetz, 2009, Cancer research.

Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX.

J. Mcarthur, Y. Ge, M. van Roey, 2001, Blood.

Anti-Tumor CC49-ζ CD4 T Cells Possess Both Cytolytic and Helper Functions

J. Mcarthur, Y. Ge, M. Moskalenko, 2000 .

Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor.

P. Hand, J. Schlom, J. Mcarthur, 1999, Human gene therapy.

Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions.

J. Mcarthur, S. Patel, Y. Ge, 2000, Journal of immunotherapy.

CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer

D. Ennist, Y. Ge, S. Ganesh, 2006, Clinical Cancer Research.

T cell-mediated elimination of cancer cells by blocking CEACAM6–CEACAM1 interaction

R. Offringa, O. von Ahsen, D. Zopf, 2021, Oncoimmunology.

Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1

F. Schuetz, F. Lasitschka, Y. Ge, 2017, Cancer Immunology, Immunotherapy.

Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study

A. Schneeweiss, F. Schuetz, Y. Ge, 2009, Cancer Immunology, Immunotherapy.

CD40L co‐stimulation from CD8+ to CD4+ effector memory T cells supports CD4+ expansion

Y. Ge, P. Beckhove, Maria Xydia, 2011, Immunology and cell biology.

Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial

W. Haefeli, J. Weitz, Y. Ge, 2015, Oncoimmunology.

Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF-β

A. Unterberg, A. von Deimling, N. Hiraoka, 2011, Clinical Cancer Research.

Tumor-Specific Regulatory T Cells from the Bone Marrow Orchestrate Antitumor Immunity in Breast Cancer

F. Schuetz, J. Weitz, Y. Ge, 2019, Cancer Immunology Research.

Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector

T. Dull, M. Kelly, J. Mcarthur, 2002, Nature Biotechnology.

Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium.

Y. Ge, N. Ramesh, M. Vanroey, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Chronic pancreatitis is associated with disease-specific regulatory T-cell responses.

M. Koch, J. Weitz, Y. Ge, 2010, Gastroenterology.

Determination of paraneoplastic autoimmune responses by tumor cell biology and intratumoral IFN-alpha/IL-12 in breast cancer patients

A. Schneeweiss, A. Scharf, F. Schuetz, 2011, Cancer Immunology, Immunotherapy.

Antigen specific T-cell responses against tumor antigens are controlled by regulatory T cells in patients with prostate cancer.

B. Hadaschik, Y. Ge, M. Hohenfellner, 2012, The Journal of urology.

Preclinical study of rAAV2-sTRAIL: pharmaceutical efficacy, biodistribution and safety in animals

Y. Ge, L. Chen, W. Li, 2017, Cancer Gene Therapy.

Novel Immunocompetent Murine Tumor Model for Evaluation of Conditionally Replication-Competent (Oncolytic) Murine Adenoviral Vectors

K. Spindler, Y. Ge, K. Jooss, 2009, Journal of Virology.

Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma.

M. Koch, J. Weitz, Y. Ge, 2009, The Journal of clinical investigation.

CG0070, a conditionally replicating GM-CSF armed oncolytic adenovirus for the treatment of bladder cancer

Y. Ge, N. Ramesh, De-chao Yu, 2005 .

Title : A novel immune-competent murine tumor model for the evaluation of conditionally replication-competent ( oncolytic ) murine adenoviral vectors

K. Spindler, Y. Ge, K. Jooss, 2009 .

Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer

M. Koch, W. Haefeli, J. Weitz, 2012, BMC Cancer.

FIX - response following administration of adeno-associated virus factor IX (FIX) immune - Factors influencing the development of an anti

J. Mcarthur, Y. Ge, S. Powell, 2013 .

Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer

Y. Ge, K. Jooss, S. Ganesh, 2009, Cancer Gene Therapy.

Death receptor 6 (DR6) is required for mouse B16 tumor angiogenesis via the NF-κB, P38 MAPK and STAT3 pathways

Y. Ge, Y. Liu, X. Yang, 2016, Oncogenesis.

HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients

F. Schuetz, C. Sohn, Y. Ge, 2013, Oncoimmunology.

Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression

L. Hawkins, Y. Ge, K. Jooss, 2008, Cancer Gene Therapy.

Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma.

M. Koch, J. Weitz, Y. Ge, 2009, The Journal of clinical investigation.